Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 4/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71964 | 1.00 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL18591950 | 0.91 | HSD11B1 (0.44) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL30289086 | 0.90 | HSD11B1 (0.42) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL30289480 | 0.90 | NR1H2 (0.51) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL24700743 | 0.90 | CHRM2 (0.47) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL22565458 | 0.89 | HSD11B1 (0.41) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL28836074 | 0.86 | HSD11B1 (0.45) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL1197096 | 0.81 | HSD11B1 (0.51) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL21577700 | 0.81 | HSD11B1 (0.51) | CHRM2CHRM1CHRM3HSD11B1CCR2 | |
| SCHEMBL30365145 | 0.81 | HSD11B1 (0.51) | CHRM2CHRM1CHRM3HSD11B1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | CHRM2 1896/4885CHRM1 1078/4885CHRM3 1886/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | CHRM2 2230/4885CHRM1 1293/4885CHRM3 2168/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | CHRM2 2033/4885CHRM1 1300/4885CHRM3 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.